Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGS MRD-Guided Blinatumomab for Pediatric B-ALL
NCT06763302Not yet recruiting
- Sponsor
- Children's Hospital, Zhejiang University School of Medicine
- Start
- Jan 2025
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
01
Overview
Randomised trial of blinatumomab in B cell acute lymphoblastic leukemia (B-ALL) (3 arms), sponsored by Children's Hospital, Zhejiang University School of Medicine. Primary endpoints: Event Free Survival at 3 years and Relapse Free Survival at 3 years. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
blinatumomab
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06763302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06763302.